Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Rilpivirine Cerebrospinal-fluid (CSF) Study

This study has been completed.
Sponsor:
Collaborator:
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT01562886
First received: March 22, 2012
Last updated: May 19, 2014
Last verified: May 2014
Results First Received: May 19, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV
Intervention: Drug: Rilpivirine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Rilpivirine and Truvada TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily

Participant Flow:   Overall Study
    Rilpivirine and Truvada  
STARTED     14  
COMPLETED     13  
NOT COMPLETED     1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Rilpivirine and Truvada TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily

Baseline Measures
    Rilpivirine and Truvada  
Number of Participants  
[units: participants]
  13  
Age  
[units: years]
Mean ± Standard Deviation
  43.8  ± 9.5  
Gender  
[units: participants]
 
Female     0  
Male     13  
Race (NIH/OMB)  
[units: participants]
 
American Indian or Alaska Native     0  
Asian     0  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     3  
White     10  
More than one race     0  
Unknown or Not Reported     0  
Region of Enrollment  
[units: participants]
 
United Kingdom     13  
Rilpivirine CSF concentration  
[units: ng/mL]
Geometric Mean ( Full Range )
  0.8  
  ( 0.54 to 1.57 )  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   CSF:Plasma Ratio of Rilpivirine Levels   [ Time Frame: Day 60 ]

2.  Secondary:   Number of Subjects With HIV Viral Load Above 50 Copies Per mL   [ Time Frame: Day 3,14, 28, 60, 80-100 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr Borja Mora Peris
Organization: Imperial College London
phone: 020 3312 6789
e-mail: b.mora-peris@imperial.ac.uk


No publications provided


Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT01562886     History of Changes
Other Study ID Numbers: 278_CSF, 2011-004026-98
Study First Received: March 22, 2012
Results First Received: May 19, 2014
Last Updated: May 19, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency